Level 3
Volume 15

Issue 2

Article 18

2020

Quality Risk Management: Seeking the Diamonds: Making the
Case for Improved Formality in QRM Decision-making
Valerie Mulholland
Technological University Dublin

Anne Greene
Technological University Dublin, anne.greene@tudublin.ie

Follow this and additional works at: https://arrow.tudublin.ie/level3

Recommended Citation
Mulholland, Valerie and Greene, Anne (2020) "Quality Risk Management: Seeking the Diamonds: Making
the Case for Improved Formality in QRM Decision-making," Level 3: Vol. 15: Iss. 2, Article 18.
doi:https://doi.org/10.21427/yfw0-hy89
Available at: https://arrow.tudublin.ie/level3/vol15/iss2/18

This PART 1: Research articles from PhD research
candidates, PRST, TU Dublin is brought to you for free and
open access by the Current Publications at ARROW@TU
Dublin. It has been accepted for inclusion in Level 3 by an
authorized administrator of ARROW@TU Dublin. For more
information, please contact arrow.admin@tudublin.ie,
aisling.coyne@tudublin.ie.
This work is licensed under a Creative Commons
Attribution-Noncommercial-Share Alike 4.0 License

Mulholland and Greene: Seeking the diamonds
Level3

December 2020

Technological University Dublin

Quality Risk Management – Seeking the Diamonds
Making the Case for Improved formality in QRM decision-making
Author
Valerie Mulholland, PhD Researcher, PRST, TU Dublin

Abstract
In November 2020, a newly formed working group of the ICH (International Council for Harmonisation
of Technical Requirements for Pharmaceuticals for Human Use) published a concept paper [1]
outlining the considerations for an update to ICH Q9: Quality Risk Management [2]. In the concept
paper, the expert group identified four areas for improvement with respect to the current application
of Quality Risk Management (QRM). One of the areas identified as problematic was a ‘lack of clarity
in risk-based decision making’. The paper described a ‘lack of clarity on what good risk-based decisionmaking means’. This paper looks at risk-based decision-making and, in particular, whether higher level
of formality in decision-making would improve the effectiveness of both QRM and KM within key
elements Pharmceutical Quality System (PQS).

Introduction
In 1921, at a presentation to the American Society of Mechanical Engineers, Frank & Lilian
Gilbreth presented the first structured method for documenting process flows [3]. The
husband-and-wife team were both Industrial Engineers and, indeed, were the pioneers of
‘time in motion studies’ – the forerunner of standardised work practices. To this day, process
flow diagrams are used in many industries to detail, analyse, and visualise the key steps in a
process. While there are some variations in notation, commonly a task is represented as a
rectangular box and a decision is a diamond. The diamond denotes the point in the process
when more than one option is available, and a decision is required.
In 2005, the pharmaceutical guidance on Quality Risk Management (QRM) – ICH Q9: Quality
Risk Management [2] – was published. It included a flow diagram to illustrate the proposed
risk management process (Fig 1). The lack of decision nodes was notable. The text of the
document pointed out that this was because decisions could occur anywhere in the process.
Risk Management is a tool to support decision-making. The objective of QRM, according to
ICH Q9, is to ‘improve science-based decision making’ within the Pharmaceutical Quality
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System (PQS). QRM informs the process owner of the hazards that must be managed,
whether the level of control applied is adequate or not, and whether action is required.
Effective quality risk management can ‘facilitate better and more informed decisions, can
provide regulators with greater assurance of a company’s ability to deal with potential risks,
and can beneficially affect the extent and level of direct regulatory oversight’
ICH Q9
However, QRM is also itself a continuum of contributary decisions - from the selection of the
appropriate risk analysis tools used to identify and rank hazards, to the risk ranking scores applied, to
the actions required to control the hazard, or to whether applied controls are adequate, etc. All these
contributory decisions cumulate within the risk management process and contribute to the
effectiveness of the outcome. It should be noted that the ICH Q9 revision concept paper listed, as
another concern, the high level of subjectivity applied in risk assessments resulting, perhaps, in a lack
of effectiveness when addressing risks. In the view of this author (with considerable auditing
experience), the provenance of some of these decisions are not always clear e.g. why a certain risk
analysis tool was selected, how the risk ranking scheme was decided, how individual ranks were
assigned, how a particular risk control was deemed to be the most appropriate, how uncertain this
decision was and whether it should be further monitored. When controlling critical quality attributes,
the output of these contributary decisions can be significant.

Figure 1: QRM Process Diagram - ICH Q9

2
https://arrow.tudublin.ie/level3/vol15/iss2/18
DOI: https://doi.org/10.21427/yfw0-hy89

2

Mulholland and Greene: Seeking the diamonds
Level3

December 2020

Technological University Dublin

Therefore, QRM is both an input to decision-making and an output of several contributory decisions both of which are important in terms of the objectives of a QRM programme. However, ICH Q9
provides little guidance in relation to decision-making or the level of formality required.
There are many, many (hundreds? thousands?) decisions made every day in a typical pharmaceutical
operation. Decisions are made every time a person does something characterised by the wordsreview, approve, evaluate, determine, check - and so on. These are common words in PQS
documentation and represent the output of decisions at all levels. However, this paper is focused on
the more impactful of those decisions. It focuses on the decisions that QRM contributes to informing,
rather than the contributary decisions that inform QRM. This paper considers how QRM, and indeed
its twin enabler Knowledge Management (KM), support the significant decision-making nodes (or
diamonds) within the PQS and whether this would be better evidenced by using formal decisionmaking processes.

What is a Decision?
There are many definitions of a decision. The Oxford Dictionary includes ‘a conclusion or resolution
reached after consideration’ and ‘the action or process of deciding something or of resolving a
question’. In his book Why Decisions Fail: Avoiding the Blunders and Traps That Lead to Decision
Debacles [4], the Ohio State University Professor Paul C Nutt, an expert in the field of strategic
management and decision-making, described decision-making ‘as taking place when a person in
authority identifies an important issue and carries out a process to make a choice that produces
outcomes with consequences’. This is a useful description for the purpose of this reflection.

The Stanford Professor Ronald Howard first coined the term ‘decision analysis’ in 1966 [5] and
he defined a decision as ‘an irrevocable allocation of resources – irrevocable in the sense that
it would be extremely costly to go back’. While this seems a dramatic definition – it does
highlight the high level of commitment that some decisions require and the need to be certain
of the outcome.
There are decisions within the PQS that are quite impactful and somewhat ‘irrevocable’, such
as deciding which equipment to purchase, what set-points, specifications, or controls to
apply; which supplier to use; whether to release a batch with an issue; what validation
strategy to adopt; whether a process is in control; whether to outsource a GMP activity; or
whether a change to a process step or test method is appropriate, etc. Decisions of this
importance may have consequences if incorrect. Turning back may also be a very difficult
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option. These are the type of decisions that this paper is concerned with, because they may
have a significant impact on product quality.
When considering these types of decisions, one ponders: Should a level of formality be required when
making decisions of this importance, such that the process of decision-making is both rigorous and
transparent? What if some of the information that informed the decision is uncertain or unreliable,
should the rationale be recorded? Does the current level of formal documentation in these systems
(change control documentation, batch manufacturing and control records, validation protocols and
reports) adequately explain the decision made? Should not the decision itself be documented,
explained and justified? Formal processes with supporting documentation can provide evidence on
how these decisions were made, given the knowledge and information available at the time.
While significant decisions are often made with a large body of evidence (knowledge) supporting the
selected option, they can also be made in novel and new contexts with a worrying lack of direct or
reliable evidence to support the outcome (risk) of the decision. These decisions are often examined in
regulatory audit. They require explanation and often also require transparency and credibility. The
level of formality applied to the decision-making, in these situations, can assist with these
explanations. These are the ‘diamonds’ within the PQS.

Critical Decision Making in a Pharmaceutical Quality System
Another ICH Guidance, ICH Q10: Pharmaceutical Quality System [6] highlights the elements
of the PQS where critical and strategic decisions are made. Decisions in these PQS elements
are important and should be evidence-based, i.e., supported with appropriate data. Decisions
on high-risk elements of the operation should, ideally, be as certain as possible. However, on
occasion these decisions can be more uncertain and are then considered risk-based decisions.
In this case, the uncertainties should be understood and managed. The PQS elements
highlighted in ICH Q10 are elements are illustrated (Fig 2).
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Figure 2: ICH Q10 Pharmaceutical Quality System Model
These elements are where the ‘diamonds’ lie – the decisions that significantly require the support of
both QRM and KM. Examples are considered for each element:
•

Process Performance and Product Quality Monitoring (PP&PQM)
Impactful decisions are made when deciding on process equipment, process settings, testing
and detection methods, or validation strategies. Containment, contamination, and cross
contamination represent some of the risks that need to be understood and controlled. With
established processes, there is typically a large body of knowledge (Knowledge Management)
to inform these decisions. Such decisions are evidence based and this evidence is normally
underpinned by good science. Occasionally novel processes, novel applications of processes,
or novel products may result in a less certain knowledge base and the consequent need to
analyse options using a risk-based approach.
Early in the pharmaceutical product lifecycle, for example in product or process development,
much may still be unknown or uncertain about the variability of processes, the causes of these
variabilities, or the relationships between variables. The relationship between the critical to
quality attributes of the product and process controls may be theoretical or assumed from
prior knowledge. As the process development cycle progresses, this understanding is
developed through modelling, experimentation, and measurement. However, product
development and process design or construction are often conducted concurrently, and
decisions may need to be made on process specifications, equipment procurement, control
systems, etc before the supporting information is fully evolved. These now become risk-based
decisions as the supporting knowledge is incomplete.
5
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As an added complication, the decision-makers in these phases of the product life cycle are
typically not the same people who manage the subsequent operation, nor those who justify
and explain these decisions to regulatory authorities. Capturing the logic of these decisions
within the Knowledge Management (KM) system is an important objective.
•

Change Management
Deciding whether to implement a change, while ensuring that there are no unintended
consequences, can represent a significant decision in the PQS. Commonly, these decisions are
based on accumulated evidence. For example, a decision to reduce sampling frequency or
sampling points is typically based on analysing the reliability of existing evidence.
However, ICH Q10 also advocates continuous improvement and innovation. True innovation
often requires novel approaches. Innovative changes may lack direct evidence and can,
therefore, represent decisions under uncertainty (risk). Such decisions are often made by a
team with diverse expertise to ensure that all relevant information (knowledge) is considered.
Change control processes typically require a high level of documentation recording the
considerations in support of the change proposal. However, they often do not offer a
complete perspective on the alternate considerations.
These types of decisions may benefit from a formal systematic approach to assure that the
value of the proposal, and all the alternative approaches, and supporting the evidence for
each option is understood. This adds a clarity as to why the particular option was chosen,
while providing evidence that alternatives were analysed and considered. It can also show
that the values and objectives of the operation e.g., product quality was central to these
considerations and that any risks were identified, monitored, and managed.
This type of approach is particularly useful if the expected benefits of the change are not
realised or if the decision has unintended consequences. What was known and understood
at the time of the decision can help manage the hindsight bias that is often prevalent when
reviewing such decisions.

•

Corrective & Preventive Action (CAPA).
Corrective actions are typically applied after an issue is detected. Issues that have an impact
on supply can introduce another decision influencing factor – urgency. The need to act quickly
can introduce an entire set of heuristics 1 and competing viewpoints into the decision-making
process. If the issue has impacted product quality or a process control that influences product
quality, then care is required to assess the available information and options in an objective
way. Formal decision-making processes or tools can assist in the endeavour, balancing the
competing objectives of urgency and accuracy, while ensuring that the decision is transparent
and evidential.
ICH Q9 strongly advocated the use of formal root cause analysis tools. While this author is not
aware of any direct empirical evidence that the use of formal tools has improved the outcome
and resolution of issues, her experience as an auditor concludes that it has certainly made it
easier to review the comprehensiveness of the investigative process and to determine the
influencing factors.
ICH Q10 also encourages preventive actions and continual improvement. These are actions
that reduce the potential for an unwanted event to occur or to improve a control. Deciding
how to act in order to correct or improve processes governed by the PQS, without

1

Heuristics are the strategies derived from previous experiences with similar problems. These strategies depend
on using readily accessible, though loosely applicable, information to solve problems.
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compromising the existing control, can require thoughtful and considered decision-making to
determine the most appropriate course of action.
•

Management Review.
Management Review provides oversight of the PQS and is the forum for providing assurance
that process performance and product quality is managed. Management must have
confidence in the accuracy and reliability of the information reviewed, i.e. that it is reliable
and that any decisions made are informed.
This is a particularly important consideration given the modern management trend towards
data visualisation. As organisations strive to get greater clarity on complex operations, there
is a growing reliance on the reductive treatments of data as trends, graphs, charts, dashboards
and other ‘business intelligence’ tools. Management Review is occasionally prone to
concluding the state of control based on concise presentations of complex data or issues,
sometimes without reference to the significance of the information in terms of reliability or
context. While data visualisation is an important clarifying concept, the decision-maker is in
danger of making subjective decisions despite the wealth of data available. While a little
knowledge is a dangerous thing, a picture that paints a thousand words without the
supporting detail may present an equal hazard.

These elements depend on the twin enablers - KM and QRM - to inform decision-making.
QRM and KM inform decision making in different ways. Knowledge, information, or data
offers the decision-maker a level of certainty and confidence when deciding. When much is
known and understood, the KM system assures that the information is available, shared, and
disseminated. It supports the decision with a weight of evidence, introducing objectivity into
the process and, consequentially, the outcome. In an ideal world – information will be
gathered to support all the alternatives. This information will be analysed, evaluated and
assessed against the objectives of the decision makers. The best option will be obvious and
will be selected. The enablers are inversely related, as knowledge grows risk decreases. [7].
(Fig 3) [8]. The journey from QRM to KM based decision-making should be mapped by a
growing body of knowledge and an associated confidence in the accuracy of that information.
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Figure 3: Risk Knowledge Infinity Cycle as applied to ICH Q10 [8]

However, many decisions are not made in ideal worlds – in reality, information may be
sketchy, inadequate or unreliable, options may be limited, or constrained by time, resources
or capacity – all of which mean that the ideal option does not clearly present itself and that
some risk or uncertainty underpins each option. When less is known or understood, the QRM
process helps the decision-maker. It can provide the tools to evaluate the limited information
available, to predict potential outcomes, and to estimate the uncertainty associated with
those outcomes.
In 1921, the Chicago based economist Frank H. Knight [9] distinguished between risk and
uncertainty. Risk, he argued, was measurable. Risk exists when the outcome of a decision is
unknown, but the chance of each outcome is measurable (probability). When throwing a dice,
for example, the outcome is unknown – but the chances of throwing a six is measurable (1/6).
When performing a risk assessment within the PQS, we analyse the various risks and assign a
probability to their occurrence. Uncertainty applies when the decision-maker does not have
information and therefore cannot determine the probability of each outcome.
When decisions are made under uncertainty, the accuracy of the outcome must be confirmed
by subsequent (rather than predictive) measurement. The requirement to establish the
effectivity of implemented CAPA actions or changes are driven by this requirement. The
uncertain elements of the process or controls are identified and are then monitored and
8
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measured and become understood. Information transforms uncertainty into knowledge. It is
important that companies and regulators alike can identify and confirm that any uncertain
outcomes of a required decision are verified to be appropriate, effective and correct.
‘Decision making is an art, only until the person understands the science’
Pearl Zhu, Decision Master: The Art and Science of Decision Making [10]

What is a Good Decision?
A simple answer might be that it is the one that results in a good outcome. However, good outcomes
may also be achieved by good luck [11], and not necessarily reflect the wisdom of the decision-maker.
Likewise, good decision-making does not prevent the possibility of a poor outcome. (However, it must
improve the chances that that will not happen.)
Another explanation of a good decision might be that looking back, and given the information available
at the time, the decision-maker would make the same decision. Hindsight is a powerful informer. The
challenge with both explanations is that the decision-maker must wait to see if they were correct.
While outcomes are the ultimate decider of the correctness of a decision, they can be a lagging
measure.
Poor decisions invite a justifiable analysis of the options and information available at the time of the
decision, highlighting the advantage of transparency in decision-making and the ability to demonstrate
how decisions were made. Impactful decisions, particularly if complex and uncertain, may lead to poor
outcomes irrespective of the thought and formality applied. Adjudicating the quality of decisionmaking by the process, rather than the outcome may be a more informative exercise. Demonstrating
what was known at the time and the reliability of the information available to the decision-maker can
be critical to defending poor outcomes.

When the decision has the potential to impact product quality or patient safety and there are
uncertainties with the applied option, then indicators or monitors must be applied to signal,
at the earliest possible opportunity, if the decision was incorrect or inappropriate.
Pharmaceutical regulators have recently highlighted the increasing numbers of defective
product on the market [12] . Whether this is connected to poor decision-making within these
processes (or poor monitoring and control), is difficult to determine. It has resulted, however,
to some discussion on the effectiveness of QRM and whether decisions relating to quality are
adequately informed. [13]
9
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A lack of formality in decision-making does not assist in the defence or understanding of these
decisions. The previously mentioned concept paper on the perceived problems with the
application of QRM notes that the industry struggles with formality and what is expected. A
recently published survey of 12 pharmaceutical companies and 11 regulatory agencies noted
that most operations ‘had a system in place to enable documentation of major decisions, however,
systems are used primarily to document outcomes rather than the process, while information from
documentation is not always used, and feedback loops are not in place’ [14].
The previously mentioned Professor Howard, one of the founders of the discipline of decision analysis,
developed a ‘Decision Hierarchy’ (Fig 4) [15] highlighting that when decisions are important or
complex, then a rigorous approach should be adopted. Proven and formal decision-making processes
or tools encourage consideration of the problem, the information and options available, and the
uncertainties involved. They also provide a justification and record of how and why a decision was
made. That there should be a high level of formality applied to important decisions within the PQS, is
consistent with the QRM principles presented in ICH Q9:
•

The evaluation of the risk to quality should be based on scientific knowledge and ultimately
link to the protection of the patient, and

•

The level of effort, formality and documentation of the quality risk management process
should be commensurate with the level of risk.

Figure 4: The Decision Hierarchy (Howard, 2000)
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Why formalise decision-making?
Decisiveness is a quality that we have come to admire in leaders. It inspires those around
them. As a result, leaders often have a bias for action and making quick decisions, occasionally
ignoring data, expertise, or details that was available at the time.
Haste in decision-making can, in complex and critical situations, overlook important detail.
Yet decisions are commonly time sensitive. To assure that all relevant information is captured
and considered, and its reliability and significance understood, and that gaps in information
are equally understood, formalising the decision-making can contribute. The industry has
already seen the benefit of formalising root cause analysis (author’s view) and the discipline
and transparency it has delivered, even in time sensitive situations – formalising decisionmaking should have a similar effect.
These time-dependent situations are fraught with heuristics, including our human
unwillingness to process large volumes of data. Complex problems require energy to resolve.
Bounded rationality2 is not uncommon when the information required to best inform a
decision is too challenging to absorb, perhaps due to the complexity of the information, the
ability of the information holder to communicate it, the ability of the decision maker to
comprehend it, or the time and attention that can be spared to considering it [16]. Whatever
the information constraints, the decision-maker consciously or unconsciously decides that the
effort is excessive, and that the problem or solution does not require that level of rational
attention. Heavy workloads often drive this approach.
Pharmaceutical manufacturing involves increasingly complex operations, with many
processes, systems, controls, data, materials, conditions, variables, and relationships.
Operations have moved from assuring process control by relying on personnel following
procedures, to reliance on an elaborate interweave of people, computerised systems,
automation, and data - all monitoring process variables.
Relationships among variables can be just as impactful as any variable in isolation. Much QRM
is assessed one-factor-at-a-time, when sophisticated modelling may be required to fully
understand these relationships. When issues present themselves or change is desirable, the

2

Bounded rationality is the idea that rationality is limited, when individuals make decisions, by the tractability
of the decision problem, the cognitive limitations of the mind, and the time available to make the decision.
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underpinning information may not be simple or complete. Information can also be dynamic
and change the understanding of the problem. It is not uncommon to note in regulatory audits
that the problem statements of issues (defined early in the process) are not ultimately reflective of
the assigned root cause (s), indicating that enhances understanding of the issue evolved as more
complete information emerged.

As discussed, modern pharmaceutical operations are complex and the ability to coherently
access and analyse a lot of information has become more challenging. Digital processes are
now part of every aspect of the supply chain and operations. As operations become more
global and computer systems form the basis of communication, the ability to maintain an
overview is reduced and employees became more siloed. According to the Harvard Business
Review [17] , fewer than 44% of employees say they know where to find the information they
need for their day-to-day work. The paper also indicates that only 25% of ‘knowledge workers’
receive effective training in information analysis and use.
In a PQS, tasks such as investigations are enabled and accelerated by access to the right data
and suitable analytical tools. Currently, complaint investigations can take up to 30 days, as
paper records and electronic data are accessed, reviewed, and analysed. Modern data mining
techniques provide opportunities to enable and enhance these processes. Therefore, data
literacy is an essential competence within modern organisations. However, formulating data
into knowledge and digital intelligence is a challenge. The need for data analytics in big data
environments is growing. However, the skills of the data miners and those of the data users
are different. One skill set does not necessarily understand the needs of the other. There are
underlying risks if data provided to a decision-maker is incomplete, inaccurate or unreliable.
Data Integrity practices and the application of the ALCOA+ 3principles in operations have
demonstrated the need to proactively manage the quality of data.
Complexity can quickly overwhelm a decision-maker, making it nearly impossible to guarantee
that each critical component of the decision is appropriately considered in the analysis [18].
Clemen & Reilly
A further consideration is the escalation processes that are often prevalent in PQS elements.
Often the ultimate approver of a decision is high in the organisation and potentially further
3 The ALCOA+ Principles are the Data Integrity Principles applied

within the pharmceutical industry. The acronym
stands for Attributable, Legible, Contemporaneous, Original and Accurate.
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from the detail of the problem. Formal decision-making processes typically offer structure to
the information supplied to decision-makers and provide higher assurance that they are
informed.
A 2015 study by the Project Management Institute [19] discovered that 47% of unsuccessful
projects were impacted by poor decision-making. While this represented a small percent of
overall projects, it was enough to encourage the organisation to prepare and publish A Guide
to the Project Management Body of Knowledge (PMBOK® Guide) [20] detailing a formal 5step framework to improve the effectiveness of decision-making. They noted a 74%
improvement in outcomes when a formal decision-making process was in place4. They key
success factors were:
•
•
•

Ensuring that decision-makers had the correct information to make decisions
That the decision makers were aligned with the overall strategy and goals
That the decision-makers paid adequate attention to risk management

Of interest in this conclusion is the contribution of both knowledge management and risk
management to the value of decision-making. Critical to decision making is knowing what is
known and understanding the reliability of what is known, knowing what is not known and
the risk with the unknown (uncertainty). The interconnected relationship between knowledge
and QRM is explored in a detailed literature review in a paper published recently by Lipa,
O’Donnell, & Greene [7].
KM can assist in creating access pathways to the correct, relevant, and current information.
QRM can provide the means to assess the validity, reliability and integrity of that information.
These challenges may not be apparent to the decision-maker. In Europe, Qualified Persons (QP) are
trained to evaluate, and critique data presented. However, this is not a universal skill among PQS
decision-makers. Alignment is needed to assure that the data presented to the user, the decisionmaker, is comprehensive and of value. Wang and Strong [21] noted that to improve data quality, data
providers need to understand what that data means to the user.

However, as mentioned previously, data complexity invites a need to visualise and reduce
information to a graph or chart. People can better understand complex data when presented
with it in a visual form. Therefore, it is becoming increasingly common to present complex

4

Note: This is not the first or most notable study to demonstrate this point. It is, however, current and in an
industry that interacts significantly with pharmaceutical manufacturing and its decision making.
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data as a visualisation. While these are useful communication tools, this reductive approach
can occasionally obscure important detail and may fail to deliver insight. The hazards in this
condensed viewpoint must be considered and managed in the process of important decision-making.

Finally, there is the fact that one decision, generally, leads to another – frequently decisions
are sequential. An early decision is made with the knowledge available at that time and, as a
result, locks the decision maker into a course of action. The next decision choice is fated by
the first. This ‘Sunk Cost’ concept [22] of decision commitment is occasionally exemplified in
a PQS through poor quality control data. Despite evidence showing the unreliability of a
committed test method, there is often a reluctance to improve the method, or to change it
altogether, to a more reliable alternative. Decisions should be viewed and managed
strategically, keeping the ultimate objectives in mind. However, this too, introduces
complexity.
ICH Q10 is clear that it welcomes improvements of this type, although there are significant
regulatory challenges with the approval complexity of post-approval changes [23].
Should all decision-making be formal?
In the first of a series of monographs published by this research unit (the Pharmaceutical
Regulatory Science Team, TU Dublin) [24] the FDA’s Gregg Claycamp highlighted the
importance of controlling subjectivity in decision-making. He advocated that a structured
approach created opportunities for identifying and controlling subjectivity, especially in
relation to risk-based decision-making. However, he also advised that such formality was not
required for all decision-making but could be limited to a small number of major decisions,
where ‘transparency, consistency and coherence’ among multiple objectives’ is required.
Formality can assist with organising the required information (or gaps) and assessing its
reliability. It can assist with assessing and managing the uncertainty with outcomes. It is not
required for ALL decisions - It must be recognised that formal decision-making takes time and
not all decisions justify this effort. If, however, a decision is clear cut i.e., one option is clearly
and obviously superior – then this level of effort is not required. If, however, there is a degree
of uncertainty with the options available and the decision might change if more was known
or understood – then the level of formality may be justified. Formality is useful when the
consequences are important, the stakes are high, and the outcomes uncertain. A key question
14
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used by NASA [25] when deciding whether to apply a formal decision process to a decision is
‘Is there a net benefit to reducing uncertainty?’, implying can we afford to get it wrong?
NASA typically apply four criteria to the decision to use formal processes. These are:
•

High Stakes
Formal process is applied when the outcome of the decision has the potential to
significantly impact costs, safety, or important objectives.
In the case of pharmaceutical manufacturing operations, a decision outcome with the
potential to significantly impact product quality, patient safety, ability to supply, or
regulatory compliance should consider the use of formal processes.

•

Complexity
If the consequences of the various options are challenging to understand without
detailed analysis, then formality should be considered. There have been several
approaches to assessing complexity in manufacturing environments [26] [27] and they
consider factors such as human factors, machine complexity, interfaces, task
complexity, process and control systems, capacity, urgency, information cues, etc.

•

Uncertainty
If there is a level of uncertainty associated with some of the inputs to the decision e.g.
insufficient data or a lack of reliable information, such that the uncertainty affects the
assessment of the alternatives, creating a risk that needs to be managed. Decision
situations may involve more than one source of uncertainty. The larger the number of
sources of uncertainty, the more complicated the decision [18].

•

Multiple Attributes
An attribute is a term in decision analysis synonymous with objective. In a typical
scenario time, cost, resources, safety, quality are all potential objectives, which may
on occasion compete for priority. The greater the number of attributes, the greater
the need for formal analysis. Formal techniques will usually require that an attribute
scale be agreed early in the process, in order to priorities or rank these competing
attributes. In pharmaceutical manufacturing, quality must be a high priority – but in
practical terms cannot come at ANY cost.
Common examples include the confidence and assurance that extensive validation
data can provide versus the cost of generating that assurance; the need to complete
an investigation to root cause versus the need to implement a timely solution; the
need to keep the cost of medicine affordable versus the expense of quality control
and assurance. Modern operations balance the need for progress and innovation with
protecting quality. To succeed the decision-maker need to understand these conflicts
and balance the trade-offs. This can be assisted through improved decision-making.
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Diversity of Stakeholders
The decision-making process also requires that the values of external ‘interested parties’ i.e.
stakeholders are understood, prioritised and included. A stakeholder is an individual or
organisation that is materially affected by the outcome of a decision. In pharmaceutical
decision-making this may include regulatory authorities, clinicians, purchasers and patients
(though perhaps not in that order). These stakeholders may not necessarily have the same
values nor place them in the same order as the decision maker.

Developing objectives hierarchies is a key tool in structured decision-making. It develops the
criteria against which alternatives will be evaluated. Therefore, criteria should be clear and
unambiguous i.e. SMART (Specific, measurable, accurate, relevant, time-based).
Earlier in this paper, the author reviewed the elements of ICH Q10 and discussed how it
represents the parts of the PQS where significant decision-making (or diamonds) occurs. One
element is change control. A change decision may represent an economic opportunity to the
organisation. The position of economic factors relative to product quality in the hierarchy of
values in the organisation should assist all decision-makers make appropriate decisions
It should be noted that in a pharmaceutical lifecycle, the values of these stakeholders may
also change. For example, when a product is new, a patient may place a high value on safety.
As the product becomes established and measured data provides assurance of safety, this
may become less important to this stakeholder and another factor, such as price, may become
more significant in rank. However, for the regulatory authority, safety may continue to be a
high priority. Likewise, if a new technology is used in a process, a regulatory authority may
place a high initial value on reliability. As this factor is assured with real time measurement,
this may become less of a priority relative to another value to this stakeholder. Acquired
knowledge is a key driver of the iterative reprioritisation of values.
Finally, there are often different perspectives when looking at the same data or information. Decision
makers frequently find themselves facing different opinions or perspectives on the required actions,
based on the same information base. This may be because experts or advisors bring different
experience or values, or it could also be due to different competencies, attitudes or risk appetite.
Understanding the drivers for those interpretations can be critical to assessing the advice. Even when
there is a common alignment on information, there may be diversions on the impact of even small
changes on the situation.
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Table 1, developed by the author, illustrates how criteria for significant decision-making
within a pharmceutical manufacturing operation could be aligned with the NASA criteria and
serve to develop a guideline for the application of formality in decision-making within the
PQS.
High Stakes
- Impacts a Critical
Control Point or
Key Parameter
associated with a
Critical to Quality
Attribute
- Impacts a test
method designed
to assure product
quality and safety
- Impacts a
Regulatory
Requirement or
commitment

Complexity

Uncertainty

- Involves a
task/step, method
recognised as
complex or critical

- Alternatives are
not supported by
reliable accurate
data

- Impacts more than
one process
and/or control
system

- Change would
significantly
reduce confidence
in state of control

- The change has
the potential to
severely disrupt
operations and
supply if incorrect

Multiple
Objectives
- Decision is highly
coupled with
another attribute
e.g., time,
resources
- A negative
outcome could
threaten the
objective of the
organisation,
including product
quality and patient
safety

Diverse
Stakeholders
- Decision is part of
a regulated system
e.g., PQS
- Decision affects a
regulatory filing
- Decision includes or
affects a third part
e.g., outsourced
activity

- Impacts ability to
supply

Table 1: Examples of Factors affecting Decision Formality

What formal models could be used?
There are a variety of models designed to support decision-making. This paper does not focus on the
various methods that could be used e.g., decision trees, influence diagrams, Multi-Criteria Decision
Making, or NASA’s Risk Informed Decision Making. This will be the topic of future work. However, all
these methods serve to document why a particular alternative was chosen above others and they
serve as a decision audit trail.

NASA’s Risk Informed Decision Making process serves as a decision audit trail and it concludes
with a ‘decision report’. Table 2 gives an outline of a NASA decision report to demonstrate
the value of structure and formality, and to illustrate the type of information trail it could
provide. This consolidation of information improves access, in the event of review or audit. It
records the information and knowledge that was available to support each decision
alternative and evaluates the reliability and sensitivity5 of that information. It demonstrates
how the uncertainties with options was assessed using risk analysis. It justifies the exclusion

5

Sensitivity: How variables are affected based on changes in other variables
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of some options with supporting rationale. It informs those affected by the decision outcome
of the outstanding uncertainties and of the performance measures required to monitor the
effectiveness of the chosen outcome.
This report can be part of the knowledge base for the organisation and be included in the knowledge
management framework.

Executive
Summary

This summary describes the problem to be solved and a general overview of each of the
alternatives.
It identifies the organizations and individuals involved in the decision-making process and
summarizes the process itself, including any intermediate downselects6.
It presents the selected alternative and summarizes the basis for its selection.

This section includes the following:
• Technical Summary: This section describes the problem to be solved and a general
overview of each of the alternatives.
• Top-level Requirements and Expectations: This section contains the top-level
requirements and expectations identified in the early steps of the decision-making
process. In cases involving diverse stakeholders, a cross reference between expectations
and stakeholder may be presented.
• Derivation of Performance Measures: This section shows the derivation of performance
measures for the decision e.g., the objectives hierarchy, a table mapping the performance
objectives to the performance measures. When constructed scales are used, the scales
are presented.

Technical
Basis for
Deliberation

• Decision Alternatives: This section shows the compilation of feasible decision alternatives
and rationales for the pruning of alternatives prior to risk analysis. Alternatives that are
retained for risk analysis are described. This section also identifies any imposed
constraints on the allowable performance measure values, and a map to the originating
top-level requirements and/or expectations.
• Risk Analysis Framework and Methods: This section presents the overall risk analysis
framework and methods used in the process. Performance parameters are identified for
each alternative.
• Risk Analysis Results: This section presents the risk analysis results and includes:
• Scenario descriptions: For each alternative, the main scenarios identified by the risk
analysis are presented.
• Performance measure Probability Density Functions (pdfs): For each alternative,
given the presence of uncertainty, the actual outcome of a particular decision
alternative will be only one of a spectra of potential outcomes for that choice and will
depend on the occurrence, non-occurrence, or quality of occurrence of intervening
events. Therefore, risk analysts model each significant possible outcome, accounting
for its probability of occurrence, in terms of the scenarios that produce it. This
produces a distribution of outcomes for each alternative - probability density functions

6

Downselect: to narrow the field of choices, especially, to choose a supplier from candidates under
consideration.
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(pdfs). All scenarios are presented along with a discussion of any significant
correlation.
• Imposed constraint risk: For each alternative, the risk with respect to imposed
constraints is presented, along with a discussion of the significant drivers contributing
to that risk.
• Supporting analyses: For each alternative, uncertainty analyses and sensitivity
studies are summarized.
• Risk Analysis Credibility Assessment: This section presents the credibility assessment
performed

Performance
Commitments:

This section presents the performance measures, ranking and risk tolerances used to
develop the performance commitments during the decision process, with accompanying
rationale.
It tabulates the resultant performance commitments for each alternative.

Deliberation:

This section documents the issues that were deliberated during decision making process.
• Organization of the deliberations: The deliberation and decision-making structure is
summarized, including any downselect decisions and proxy decision-makers.
• Identification of the contending decision alternatives: The contending alternatives are
identified, and rationales given for their downselection relative to the pruned
alternatives. Dissenting opinions are also included.
• Pros and cons of each contending alternative: For each contending alternative, its pros
and cons are presented, along with relevant deliberation issues including dissenting
opinions. This includes identifying violations of significant engineering standards, and
the extent to which their intents are met by other means.
• Deliberation summary material: Briefing material, etc., from the deliberators and/or
risk analysts to the decision

Alternative
Selection:

This section documents the selection of an alternative
• Selected alternative: The selected alternative is identified, along with a summary of the
rationale for its selection.
• Performance commitments: The finalized performance commitments for the selected
alternative are presented, along with the final performance measure risk tolerances and
performance measure ordering used to derive them.
• Risk list: The risk list for the selected alternative is presented, indicating the risksignificant conditions extant at the time of the analysis, and the assessed impact on the
ability to meet the performance commitments.
• Decision robustness: An assessment of the robustness of the decision is presented.

Table 2: Example of Content in NASA Decision Report [25]

Conclusion
Pharmaceutical regulations currently require a degree of evidence to support decisionmaking e.g., who made the decision, the date, the supporting evidence, etc. Significant
decisions are made within the PQS elements and these require accountability and traceability.
These are the ‘diamonds’ which assure product quality. These ‘diamonds’ are not in the QRM
process flow chart from ICH Q9, they are within the PQS elements that QRM and KM support.
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Diamonds are one of the strongest materials on earth, due to the strength of the supporting
bonds. Significant PQS decisions should be equally strong, supported by the twin enablers of
QRM and KM.
Diamonds are also valuable and (to stretch an analogy, even further) there is also value in
improved formality around critical decisions within the PQS. For these types of decisions,
having a structure to organise and understand the reliability of the supporting information,
to clarify and detail the range of options available, to demonstrate why and how an option
was taken, can only contribute positively to the accuracy, transparency, and traceability of
these decisions. With complex decisions, this will also add clarity to the uncertainties or risks
that should be subsequently monitored to assure an accurate outcome, or, inversely, it will
inform the signals that should be applied for early indications of concerns.
Pharmceutical operations should seek to identify the type of decisions that would benefit
from formality and may find the criteria used by NASA useful – high stakes, complex, a degree
of uncertainty, multiple objectives and stakeholders. This work – looking to the stars to
resolve diamonds - will be continued by this author.
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